The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Distinctive clinical and molecular aberrations of colorectal cancer patients with ovarian metastases.
 
Alexandria Lenyo
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie
 
Cathy Eng
Consulting or Advisory Role - Abbvie; Amgen (I); California Institute for Regenerative Medicine (CIRM) (I); Hookipa Biotech; IgM Biosciences (I); Merck Serono; Pfizer; Seagen; Taiho Oncology (I); Takeda
Research Funding - Gritstone Bio (Inst); Hutchison MediPharma (Inst); Janssen Oncology (Inst); Merck (Inst); Pfizer (Inst); Sumitomo Dainippon Pharma Oncology (Inst)
 
Deepa Magge
No Relationships to Disclose
 
Kristen Keon Ciombor
Consulting or Advisory Role - Bayer; Exelixis; Incyte; Lilly; Merck; Personalis; Pfizer; Replimune; Seagen
Research Funding - Abbvie (Inst); Amgen (Inst); Array BioPharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Incyte (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); Nucana (Inst); Onyx (Inst); Pfizer (Inst); Pfizer/Calithera (Inst); Sanofi (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Array BioPharma; Incyte